1. Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P (2014) Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol 48(5):426–435
2. Tombal B (2012) Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol Off J Eur Soc Med Oncol Suppl 10: x251–2x58.
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, (AWMF) (2016) Konsultationsfassung: Interdisziplinäre Leitlinie der Qualität S3 zur Früherken-nung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Lang-version 4.0, 2016 AWMF Registernummer: 043/022OL,
https://leitlinienprogramm-onkologie.de/Prostatakarzinom.58.0.html
. Accessed 20 Nov 2018
4. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
5. American Urological Association (2018) [Internet]. [cited 2018 Nov 10].
https://www.auanet.org/guidelines/prostate-cancer-clinically-localized-(2017)
. Accessed 20 Nov 2018